Drugs for dermatological disorders (A61P17)

A   Human necessities(308424)
A61P17                 Drugs for dermatological disorders(1612)
External application means for chronic dermatosis treatment, and method for its production // 2628535
FIELD: medicine.SUBSTANCE: invention can be used as a preventive and therapeutic agent with anti-inflammatory and antibacterial properties, intended for external use, for treatment of all kinds of chronic dermatoses: dermatitis, neurodermatitis, furunculosis, eczema, fungal diseases, parasitic skin diseases, acne, and method for its production. The external agent for treatment of chronic dermatitis in the form of an aqueous suspension of mercuric monochloride is prepared by a process comprising premixing of powdered mercury monochloride with nitric acid at the following ratio of components, wt %: mercury monochloride 0.3-0.6; nitric acid 0.6-1.0, at a temperature of 70-90°C, stirring for 1 hour. Then the obtained solution is mixed with water of high mineralization from the "Belaya Gorka" mineral source to 100 wt %. At that, the pH of the obtained suspension is adjusted to 1-2 with nitric acid.EFFECT: increased efficiency of treatment.2 cl, 7 ex
Short antimicrobial lipopeptides // 2627648
FIELD: medicine.SUBSTANCE: invention relates to a method for mammal skin or mucosal tissue microbial infection treatment comprising administration of a therapeutically effective amount of a composition comprising at least one peptide of formula Pal-lipid-lysine-proline-NH2 or Pal-lipid-lysine-d-proline-NH2, and a pharmaceutically acceptable carrier for an effective amount of time to the infected area.EFFECT: invention provides treatment of mammal skin or mucosal tissue microbial infections.6 cl, 1 ex, 4 tbl
Cosmetic means with mineral thermal water "dzhemukhskaya tselebnaya" // 2627619
FIELD: cosmetology.SUBSTANCE: cosmetic means for skin with mineral thermal water "Dzehmukhskaya tselebnaya", containing a thick licorice root extract dissolved in thermal water, silver sulfate, peppermint or lavender essential oil, at that "Dzehmukhskaya tselebnaya" medium-high mineralized thermal water with a standard content of biologically active boron 40-80 mg/dm3 in H3 BO3 acid and silicon 110-140 mg/dm3 in H2SiO3 acid and pH medium reaction of 6.5-7.0 is contained as the thermal water.EFFECT: cosmetic means has a tonic, moisturizing, softening and refreshing properties, it helps to eliminate disturbances in sebaceous glands secretion, skin texture.4 tbl
ethod for atrophic skin scars treatment // 2627468
FIELD: medicine.SUBSTANCE: fully straightened filtered radio waves of high frequency, obtained by the radio wave device Surgitron®, and an autologous platelet-rich plasma are used. At that, blood is taken from the peripheral vein of the patient into vacuum tubes. Blood is mixed with an anticoagulant. The blood mixture is then centrifuged with an anticoagulant for 4-6 minutes at a centrifuge rotation speed of 700-900 rpm. After that, the upper layer of the platelet-rich plasma is extracted into a separate tube and activated by calcium ions by addition of calcium gluconate. The activated platelet-rich plasma is placed into the syringe and injected intradermally into the scar. The injected region is then warmed up to 41-43°C by the Surgitron® radio wave device with Pelleve® ClideSafe electrodes or PelleFirm for at least 4 minutes.EFFECT: invention allows to shorten the time of scars treatment in patients.11 cl, 1 ex
ethod of lichen planus treating // 2627456
FIELD: medicine.SUBSTANCE: invention can be used to treat lichen planus (LP). The method includes taking a patient of prednisolone in an average daily dosage (SDS) of 30 mg, hydroxychloroquine in the SSD of 400 mg, mebhydroline in a 200 mg SDO, 25 mg of hydroxysine, external betamethasone cream. In addition, the patient additionally takes Noophen in a dose of 250-500 mg, three times, after meals, with the first reception of Noophen preparation prescribed for 3 hours before a single daily session of TPP therapy with bipolar current in the 70 Hz mode, starting at a current of at least 2.0 MA, in each subsequent procedure the current is increased by 0.2-0.4 mA, under the control of the clinical effect and the patient's condition after each procedure, the procedure time is 30-40 min, the course is 6-12 procedures.EFFECT: use of the invention makes it possible to shorten the time of systemic and topical application of hormonal drugs, to achieve a longer remission; eliminate cosmetic defects, improve the quality of life of patients.2 ex
ethod of treatment of epithelial pilonidal sinus at the stage of abscedation // 2627350
FIELD: medicine.SUBSTANCE: after excision of the epithelial pilonidal sinus with the abscess shells, the wound bottom is treated for 5 minutes with a gas stream containing the nitrogen monoxide of the Plazon apparatus in the NO-therapy regime. After suturing and vacuum drainage of the wound along the Redon, deviating from the left and right edges of the ends of the postoperative wound, is administered subcutaneously in a solution of 32 units of lidase. 10 minutes after the administration of lidase, retreating to 1 cm from the place of its introduction, injected subcutaneously in a solution of 50 mcg of immunophane. The administration of lidase and immunofan is repeated after 48 hours in combination with the treatment of the postoperative wound for 5 minutes with nitrogen monoxide in the NO-therapy regimen.EFFECT: method allows to improve the results of treatment of patients with epithelial coccygeal circulation at the stage of abscess formation, due to the combined and complex effect on the wound and its area.3 dwg, 1 ex
ethod of treatment of central scrolleromy // 2627153
FIELD: medicine.SUBSTANCE: for the treatment of focal scleroderma, lesions are affected by low-energy laser radiation of the infrared range with a repetition rate of 1500 Hz, a pulse duration of 110-160 ns, a pulse power of 4-6 W/pulse, and 1-3 minutes per field. The total duration of exposure is no more than 15 minutes. Immediately before exposure to laser radiation on the scleroderma foci impose a gel for the body NOLLA naturelle®. In this case, exposure to laser radiation alternates every other day with paraffin applications on scleroderma foci, at a temperature of 48-52°C, time 20 minutes. The course of treatment is 8-10 complex procedures.EFFECT: method provides a multifactorial effect on all parts of metabolic processes in pathologically altered fibrotic dermal foci with a reduction in side effects and contraindications to the treatment.2 ex

Prodrug compositions with high degree of penetration based on peptides and related compounds // 2627065
FIELD: pharmacology.SUBSTANCE: invention relates to compositions with a high degree of penetration or prodrugs with a high degree of penetration based on a peptide or a peptide-related compound that contain a functional unit, a linker and a transport unit. The functional unit is covalently bound to the transport unit via the linker and comprises a peptide or peptide-related compound fragment. The transport unit comprises an amino group capable of being protonated. The linker comprises a bond capable of cleavage after composition penetration through a biological barrier.EFFECT: increased penetration.27 cl, 2 dwg, 16 tbl, 6 ex

ethods of production isoquinolinones and solid forms isoquinolinones // 2626883
FIELD: chemistry.SUBSTANCE: invention relates to new polymorphic forms of the compounds of formula (I), having inhibitory action against phosphoinositide 3-kinase (PI3K). The compounds may be used to treat cancer, such as leukemia, lymphoma, inflammatory disease and autoimmune disease. The polymorphic forms of the compound of formula (I) is the polymorphic form C of the hydrate of the compound of formula (I), which has characteristic peaks in the x-ray powder diffraction pattern (XRPD) 2θ=10.4°(±0.2°), 13.3°(±0.2°) and 24.3°(±0.2°); Polymorph A, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=9.6°(±0.2°), 12.2°(±0.2°), and 18.3°(±0.2°); Polymorph B, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=7.9°(±0.2°), 13.4°(±0.2°), and 23.4°(±0.2°); polymorphic form D, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=11.4°(±0.2°), 17.4°(±0.2°), and 22.9°(±0.2°); polymorphic form E, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=6.7°(±0.2°), 9.3°(±0.2°) and 24.4°(±0.2°); Polymorphic form F, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=9.6°(±0.2°), 17.3°(±0.2°), and 24.6°(±0.2°); Polymorphic form G which is the solvate of the tert-butyl methyl ether of the compound of formula (I) and has characteristic peaks in the powder XRPD pattern 2θ=6.7°(±0.2°), 9.5°(±0.2°) and 19.0°(±0.2°); Polymorphic form H, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=8.9°(±0.2°), 9.2°(±0.2°) and 14.1°(±0.2°); Polymorphic Form I, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=9.7°(±0.2°), 19.3°(±0.2°), and 24.5°(±0.2°), and the polymorphic form J, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=9.1°(±0.2°), 17.3°(±0.2°) and 18.3°(±0.2°). The invention also relates to a process of preparing form C. For example, mentioned process comprising (i) exposure of the medium containing water, a composition comprising at least one polymorphic form, not a form of a compound of formula (I), for a period time sufficient for the transformation, preferably for 18-24 hours, at least 50% of the total amount of the polymorphic form (s) a non-form C; and (ii) recovering mentioned polymorph form C.EFFECT: high effectiveness of compounds.84 cl, 31 dwg, 16 tbl, 42 ex
eans for treatment of skin and mucosa diseases, for local use, which is anti-inflammatory, anti-bacterial, antiviral, wound-healung, anti-fungal // 2626673
FIELD: pharmacology.SUBSTANCE: means for skin and mucosa diseases treatment, which has anti-inflammatory, anti-bacterial, antiviral, wound-healing, anti-fungal activity, is a Gynura Procumbens leaf hydrolyte obtained by steam or water distillation of fresh or dry leaves of Gynura Procumbens at a fresh leaves and water ratio of 1:3-6 or at a dry leaves and water ratio of 1:30-60.EFFECT: means has a high efficiency for treatment of skin and mucosa diseases due to pronounced anti-inflammatory, anti-bacterial, antiviral, wound-healing, anti-fungal action.1 tbl, 13 ex
Drug for body soft tissue disorders treatment // 2626671
FIELD: medicine.SUBSTANCE: proposed drug has the form of a powder and contains a nitrogen-containing drug substance that generates nitrogen monoxide in the affected tissue, namely sodium nitrite or nitrofural or furazoline or furadonin or furagin or its potassium salt or metronidazole or nitroxoline, as well as cytochrome C, ascorbic acid or sodium ascorbate, zinc oxide, and auxiliary substances (starch or sodium salt of carboxymethyl cellulose, or hydroxypropyl cellulose or hydroxypropylcellulose) and talc.EFFECT: implementation of the invention allows to obtain a drug exhibiting high efficacy in treatment of long-lasting body soft tissue damages, including wounds, burns, trophic skin ulcers, pressure ulcers and other various skin lesions.3 cl, 3 tbl, 16 ex
ethod for treatment of hypercorrection arising in case of contour plastics by gels based on hyaluronic acid // 2626588
FIELD: medicine.SUBSTANCE: defect is localized by ultrasound. Correction is carried out in 2 stages. First, phonophoresis with 1% hydrocortisone ointment is applied to the corresponding corrected zone, daily for 4 minutes and for 6-10 sessions. After 3 weeks, ultrasound monitoring is performed. After that, also under the ultrasound control, "Longidaza" at a dose of 75-150 MU is injected into the areas of undissolved gel exceeding 3 mm in size, bypassing the adjacent vessels and nerves. After 2 weeks, a repeated control ultrasound is performed to confirm the absence of undissolved gel patches.EFFECT: method allows to obtain the desired aesthetic result, to shorten the period of medical and social rehabilitation.2 ex
N-(pyrid-4-yl) amides and n-(pyrimidin-4-yl) amides and their pharmaceutical and cosmetic application // 2625789
FIELD: pharmacology.SUBSTANCE: invention relates to new N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides of formula (1) or their pharmaceutically acceptable salts having the properties of androgen receptor inhibitor (AR). The compounds can be used for pharmaceutical or cosmetic composition to treat androgen-dependent disease or disorder. These diseases include dermatological diseases or disorders such as diseases or disorders of sebaceous gland (glands); acne; hyperseborrhea; greasy skin; seborrheic dermatitis; hyperpilosity or hirsutism; atopic dermatitis or androgenic alopecia. In N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl) amides of formula (1) , R1 is C1-6 alkyl, C3-7cycloalkyl, C1-6alkyloxy, -S(O)m-C1-6alkyl, C1-6fluoroalkyl, C1-6fluoroalkyloxy, C1-6alkyl-OH, -(CH2)iC1-6alkyloxy, -(CH2)j1-O-C1-6fluoroalkyl, CORa, CN, NO2, NR5R6 or halogen atom; R2 ishydrogen atom, methyl, methoxy or bromine atom; R3 and R4 are the same or different and represent hydrogen atom, C1-12alkyl, C3-9cycloalkyl, C1-6fluoroalkyl, -C1-6alkyl-OH, -(CH2)p-C1-6alkyloxy, -(CH2)q-C3-9cycloalkyl, -(CH2)rC1-6fluoroalkyl, -(CH2)s-O-C1-6fluoroalkyl, phenyl, heteroaryl, heterocyclyl group, -(CH2)t-phenyl or -(CH2)v-heteroaryl, where each phenyl and heteroaryl are optionally substituted with 1-3 same or different groups of Rc; as well as R3 and R4 together with carbon atom carrying them can form C3-9cycloalkyl group or heterocyclyl group, such as tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydro-1-oxo-thiopyranyl or tetrahydro-1.1-dioxo-thiopyranyl; Rc is C1-6alkyl, C3-7cycloalkyl, C1-6alkiloxi, -S(O)u-C1-6alkyl, C1-6fluoroalkyl, C1-6fluoroalkyloxy, C1-6alkyl-OH, CORd, CN, NO2, NR9R10, OH or halogen atom; Ra and Rdare the same or different and represent C1-6alkyl, C1-6alkyloxy or NR7R8; R5, R6, R7, R8, R9 and R10 are the same or different and represent hydrogen atom, C1-6alkyl, C3-7cycloalkyl or -(CH2)w-C3-7cycloalkyl; as well as R5 and R6 together with nitrogen atom carrying them can form heterocyclyl group; as well as R7 and R8 together with nitrogen atom carrying them can form heterocyclyl group; as well as R9 and R10 together with nitrogen atom carrying them can form heterocyclyl group; i, j, p, q, r, s, t, v and w are different or the same and represent 1, 2 or 3; n and u are different or the same and represent 0, 2 or 2; and X represents CH or N.EFFECT: improved properties of compounds.22 cl, 4 tbl, 80 ex
ethod of correction of the age-related face skin changes // 2625548
FIELD: cosmetology.SUBSTANCE: method includes intradermal injection of the "Hyalual" preparation containing unstabilised hyaluronic acid and succinate. In the treated area, skin tension lines are marked and "Hyalual" 2.2% 1-2 ml is injected in small doses into the middle layer of the derma between the reference zones along the indicated tension lines by retrograde short-line technique, with the needle inserted into the skin at an angle of 30-45° to the middle or 1/3 length.EFFECT: increased effectiveness of correction of the age-related face skin changes by increasing the therapeutic effect of the Hyalual preparation by means of optimising the scheme and techniques of its injection.1 dwg
Pharmaceutical aerosol composition and method for pharmaceutical composition production // 2625504
FIELD: pharmacology.SUBSTANCE: pharmaceutical drug composition for treatment of wounds and other skin defects consists of 0.1-99.9% vinyl butyl polyether, 0.1-99.9% of low boiling aliphatic ester as a solvent, and a pharmaceutically acceptable carrier gas. Diethyl ether is used, in particular, as a low-boiling aliphatic ester.EFFECT: method for pharmaceutical composition preparation is based on vinyl butyl polyester dilution in low boiling aliphatic ether, sterile filtration and applicator filling under pressure, together with a carrier gas dose under conditions ensuring mixture sterility.10 cl, 4 ex, 2 tbl
ethod for personified photodynamic therapy of extensive cosmetic skin defects // 2625297
FIELD: cosmetology.SUBSTANCE: drug based on 5-aminolevulinic acid is applied on the entire face and / or head skin. After 1 hour after drug application on skin, fluorescence spectroscopy is carried out, determining the fluorescence intensity (FI), on the basis of which a dose of laser irradiation for PDT is chosen from the range of 5-45 J/cm2. The lower the FI, the smaller the dose of irradiation. PDT irradiation of the entire skin is carried out using laser radiation with a wavelength of 400-800 nm.EFFECT: method allows to increase the PDT efficiency of extensive cosmetic skin changes due to personified selection of the therapeutic dose of laser irradiation taking into account the quantitative measurement of accumulation level of 5-ALA of induced protoporphyrin IX by fluorescence spectroscopy method.4 dwg, 2 ex
Seborrhea treatment // 2624238
FIELD: medicine.SUBSTANCE: method for seborrhea treating is described and comprises administration of an effective amount of (24RS)-scymnol or (24S)-scymnol, an ester thereof or a pharmaceutically acceptable salt thereof or of (24R)-scymnol. (24RS)-scymnol or (24S)-scymnol, an ester thereof or a pharmaceutically acceptable salt thereof or of (24R)-scymnol reduces sebum during seborrhea treatment.EFFECT: increased efficiency of treatment.12 cl, 4 dwg, 2 ex
ethod for complications prevention in postoperative period during surgical treatment of nasal polyposis // 2624234
FIELD: medicine.SUBSTANCE: nasal cavity is cleaned and then washed with in octenisept solution diluted 1:5 with distilled water, followed by endaural electrophoresis with application of Fermenkol, after electrophoresis, reconstructed nasal cavity tamponade is performed using Fermenkol-gel impregnated turundas.EFFECT: invention provides minimization of postoperative complications, namely, reduction of inflammation severity, reduction of adhesions, elimination of incomplete epithelialization of nasal mucosa, improvment of nasal functions.4 cl, 3 ex
Oxazethydine derivatives, method for their production and their use in medicine and cosmetics // 2624011
FIELD: chemistry.SUBSTANCE: invention relates to a heterocyclic compound of formula (I) and its enantiomer where R1 is a cyclopropylmethyl group, and R2 represents a methyl group; or R1 represents a 4-hydroxybutyl group, and R2 represents a hydrogen atom. The invention also relates to use of a formula compound (I) or compositions on the basis thereof, pharmaceutical compositions and cosmetic compositions based on compounds of formula (I).EFFECT: obtained new compound is useful in the treatment of pigmentation disorders and inflammatory or immune disorders.12 cl, 2 tbl, 3 ex
Hydrophilic ointment for infected wounds treatment // 2623874
FIELD: pharmacy.SUBSTANCE: hydrophilic ointment for infected wounds treatment, comprising poviargol, methyluracilum, methylcellulose, water, taken at a certain component ratio.EFFECT: ointment reduces inflammation period, accelerates epithelialization and is non-toxic.1 tbl, 8 ex
Silicon-zinc-boron-containing glycerogydrogel for local application, facilitating for vulnerary, regenerative, bactericidal and antifungal activity // 2623153
FIELD: pharmacology.SUBSTANCE: invention is a silicon-zinc-boron-containing glycerogyrogel for topical application, with wound-healing, regenerative, bactericidal and antifungal activity, with composition corresponding to the formula mSi(C3H7O3)4⋅ZnC3H6O3⋅nHB(C3H6O3)2⋅xC3H8O3⋅yH2O, where 1≤m≤3, 1≤n≤2, 9≤x≤15, 28≤y≤70, obtained by interaction of silicon tetraglycerolate in an excess of glycerin Si(C3H7O3)4⋅xC3H8O3, where 1.5≤x≤4.5, zinc monoglycerolate in excess of glycerin⋅ ZnC3H6O3⋅6C3H8O3, boron bisglycerolate HB(C3H6O3)2 and water in a molar ratio of Si(C3H7O3)4:ZnC3H6O3:HB(C3H6O3)2:C3H8O3:H2O, equal to (1÷3):1:(1÷2):(9÷15):(28÷70), at a temperature of 40-60°C and stirring.EFFECT: creation of a product that is safe to use and has a wide range of pharmacological activities - wound healing, regenerating, bactericidal and fungistatic, in a convenient form for topical application, storage stable, well reproducible in the production process using available raw materials.2 tbl, 5 ex
eans for skin diseases treatment have anti-inflammatory, wound-healing, antibacterial, anti-viral, anti-fungal action // 2623061
FIELD: pharmacology.SUBSTANCE: invention relates to a skin treatment agent having an anti-inflammatory, anti-bacterial, anti-viral, anti-fungal activity that is an oil extract of Gynura procumbens leaves obtained in a specific manner.EFFECT: agent is effective for skin diseases treatment.6 cl, 16 ex
Adhesive composition and method for its application // 2623060
FIELD: medicine.SUBSTANCE: adhesive composition and method for its application are described. The adhesive composition includes silver particles stabilized by submicron particles of titanium dioxide and a filler, according to the invention, a mixture of phenol-formaldehyde resins, polyvinyl butyral, dibutylphthalate, castor oil and rosin components is used as a filler at a certain component ratio. A method is described which comprises adhesive composition application to a postoperative wound or suture at a dose of 0.5-1.0 mg/cm2, once.EFFECT: method eliminates the development of postoperative inflammation due to prolonged preservation antibacterial properties, has a pronounced immobilizing effect on the surgical wound edges, improving the quality of the joined surface.2 cl, 5 tbl
Hydrogen cocktail with high antioxidant activity // 2622764
FIELD: pharmacology.SUBSTANCE: invention relates to a composition with antioxidant activity having an oxidation-reduction potential of minus 600 to minus 50 mV and being water saturated with hydrogen, consisting of pure water dissolved therein under the pressure of molecular hydrogen and an antioxidant, wherein the antioxidant is contained in the concentration of up to 100 mg/l and is selected from: vitamin C, retinol and dihydroquercetin.EFFECT: implementation of the invention allows to obtain a hydrogen cocktail with increased AOA.1 cl
Furo[3,2-b]- and thieno[3,2-b]pyridine derivatives as tbk1 and ikkε inhibitors // 2622034
FIELD: pharmacology.SUBSTANCE: invention relates to a novel compound of formula I , wherein X means O or S, R1 means O(CYY)nHet1 or O(CYY)nCyc, R2 means Ar or Het2, Het1 means pyrrolidinyl, tetrahydro imidazolyl, dihydropyrazolyl, tetrahydropyrazolyl, tetrahydropyranyl, dihydropyridyl, tetrahydropyridyl, piperidinyl, morpholinyl, hexahydropyrimidinyl, azepanyl, tetrahydrofuranyl, furyl, thienyl, pyrazolyl, pyridyl, chromanyl or piperazinyl, each of which is unsubstituted or monosubstituted by A, COOA, OY and/or =O (carbonyl oxygen), Het2 means mono- or bicyclic saturated, unsaturated or aromatic heterocycle which contains from 1 to 2 N, O and/or S atoms, which may be unsubstituted or monosubstituted by A, (CYY)p-OY, (CYY)p-Het1, -CO-Het1 and/or =O, Ar means phenyl, which is unsubstituted or monosubstituted by Hal, A, (CYY)p-OY, (CYY)p-Het1, (CYY)p-COOY, CO(CYY)pNH2, CO-NYA, CONY(CYY)mNYCOOA, CO-Het1, O(CYY)p-NYY, CONY(CYY)pHet1 and/or CONH(CYY)pNHCOA, Y means H or an alkyl, which contains 1, 2, 3 or 4 C-atom, A is an unbranched or branched alkyl that contains from 1 to 10 C-atoms, Cyc means a cycloalkyl, which contains from 3 to 7 C-atoms, which is unsubstituted or monosubstituted by A, Hal means F, Cl, Br or I, n means 0, 1 or 2, m means 1, 2 or 3, p means 0, 1, 2, 3, or 4 and pharmaceutically applicable salts and stereoisomers thereof, including mixtures thereof in all ratios.EFFECT: compounds are inhibitors of TVK1 and ε IKK, and can be used in particular for the treatment of malignant neoplasms and inflammatory diseases.6 cl, 3 tbl, 120 ex
Application of "triderm" for wound treatment and skin transfer // 2622012
FIELD: pharmacology.SUBSTANCE: treatment of wounds and skin cuts with a "Triderm" cream is shown without change of skin pigmentation, no burning or allergic reactions was observed; engraftment of a separated piece of skin is prescribed.EFFECT: cream or ointment creates conditions for tissue regeneration.2 cl
ethod for non-oncologic cosmetic skin defects photodynamic therapy // 2621845
FIELD: medicine.SUBSTANCE: photosensitizer based on 5-aminolevulinic acid is applied to the affected skin areas. An hour later PDT session is performed on these sites by means of laser radiation with an energy of 30-150 j/cm2, wavelength of 630 nm. 60 minutes after the end of the PDT session, low-intensity laser irradiation with a wavelength of 850-900 nm is conducted on the entire PDT-exposure area. Exposure takes 2 to 25 minutes.EFFECT: method allows to improve the efficiency of PDT for extensive cosmetic changes of skin by reducing inflammatory skin reactions as a result of low-intensity laser irradiation.3 ex
Pyrazole quinolinone derivatives, their preparation and therapeutic application // 2621037
FIELD: pharmacy.SUBSTANCE: invention relates to compounds according to formula (I) , wherein R1, R2 and R3 are as defined in claim cl. 1. The compounds of this invention are reversible and selective inhibitors of type 2 methionine aminopeptidase (MetAP2). The invention also relates to intermediates for preparing the compounds of formula (I), drug and pharmaceutical compositions based on the compounds of formula (I) and their therapeutic application.EFFECT: increased efficiency of compounds application.24 cl, 2 tbl, 25 ex
eans of antimicrobial, reparative and anti-inflammatory action // 2620564
FIELD: pharmacology.SUBSTANCE: means includes a dry extract from shoots of golden rhododendron containing a sum of simple phenols and phenolic glycosides of at least 28%, obtained by raw materials extraction with a particle size of 2-3 mm with water purified at raw material and extractant ratio of 1:10, extraction time for the first phase contact is 2 hours, for the second - 1.5 hours, for the third - 1 hour, with raw material stirring and temperature of 60±5°C.EFFECT: invention has a pronounced antimicrobial, reparative and wound healing activity.2 cl, 1 dwg, 11 tbl, 1 ex
ethod for treatment of heavy forms of psoriasis // 2620552
FIELD: medicine.SUBSTANCE: complex treatment is performed, including introduction of drugs to improve microcirculation, desensitizing and de-intoxication means, local therapy and introduction of stemokin immunomodulator. Stemokin is injected intramuscularly, 1 ml of solution for 7 days, a two-day break is made, the course of treatment is repeated. Next, stemokin is injected intramuscularly in the form of spray into each nasal passage 2 times a week for 2 months.EFFECT: achievement of a pronounced clinical remission and lengthening of the inter-recessive period.10 tbl, 1 ex
ethod for treatment of patients with trophic ulcers // 2620498
FIELD: medicine.SUBSTANCE: ulcer surface is treated with a tampon moistened with saline. Single cryogenic action with liquid nitrogen with a temperature of -180°C and exposure time max. 5 seconds is performed, by the maximum cooled applicator with different diameters of flat working surface. Three to six days after cryoexposure, the formed layer of the affected tissue is removed by hydropressive treatment of ulcer with an ultrahigh-pressure microdispersion fluid stream with an outlet pressure of 120-150 atm, from a distance of 15-20 cm from the nozzle system end to the ulcer surface, at an angle of 40-45° relative to the ulcer surface. In this case, if the ulcer significantly exceeds the applicator surface, the latter is progressively moved to cover the entire surface of the wound, without staying at each site for more than 5 seconds.EFFECT: method allows to shorten the time for trophic ulcers preparation to active closure by skin grafting or application of collagen-containing drugs, eliminates perifocal inflammation and reduces the risk of infectious process development.3 cl, 2 ex, 4 dwg
Treatment method of chronically non-healing wounds // 2620336
FIELD: medicine.SUBSTANCE: invention refers to the medicine, particularly, to the surgery, and may be used for the treatment of chronically non-healing wounds. For this purpose, on the treatment day 1, 4, 7, 10, and 13, the solution of alpha-interferon at the total dosage of 3 mln UA is injected uniformly to the bottom and along the external edges of a wound at the depth of 10 mm. Common reproduction in the outpatient conditions.EFFECT: method allows reducing a period of healing of post-operation wounds and improving the quality of life of patients by means of local immunity stimulation with the further development of active granulations.3 ex
ethod for obtaining preparation for stimulation of regeneration based on products of secretion of human multipotent mesenchymal stromal cells // 2620167
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and can be used for obtaining biomaterials for stimulation of tissue regeneration after injury. Method of preparation obtaining includes cultivation of human mesenchymal stromal cells of adipose tissue (MSC AT) to 4-5 passage in medium, supporting growth of non-differentiated human mesenchymal cells. Washing of cells with buffer solution, conditioning MSC AT in serum-free and deprived of animal-derived products growth medium, supporting cell viability not lower than 79% and suitable for therapeutic application, are performed. After sampling cultivation medium, containing products of human MSC AT secretion, remnants of cells are removed from it with purification from low-molecular components with the following lyophilisation of purified cultivation medium. Preparation contains products of human MSC, including key growth factors: VEGF in concentration not lower than 200 pkg/ml, HGF in concentration not lower than150 pkg/ml, FGF basic in concentration not lower than 0.29 pkg/ml, angiopoietin-1 in concentration not lower than145 pkg/ml, PEDF in concentration not lower than 500 pkg/ml, determined by method of enzyme immunoassay with reduction of lyophilisate in sterile physiological solution. Preparation efficiency is provided due to selected content in medium of key growth factors, required for realisation of regenerative MSC action, namely vessel endothelium growth factor (VEGF), hepatocyte growth factor (HGF), basic fibroplast growth factor (bFGF) and angiopoietin of type1 (Angpt-1), as well as antiangiogenic factor, obtained from pigment epithelium cells (PEDF).EFFECT: application of the obtained preparation makes it possible to stimulate tissue regeneration in efficient way due to complex balanced action of growth factors and other biologically active molecules, secreted by human mesenchymal stem/stromal cells (MSC) into culture medium, which does not contain xenogenic components.12 cl, 9 ex, 6 dwg
Compositions for treatment of peripheral ulcers of different origin // 2619853
FIELD: pharmacy.SUBSTANCE: composition for treatment of ulcers caused by blood stasis in the lower limbs veins, comprising: 0.05 to 2% of anthocyanosides bisulfite adducts derived from myrtifolious bilberry (Vaccinium myrtillus) extracts, in pure form or in the form of containing extracts, 0.01 to 1% of lipophilic extract of narrow-leaved (Echinacea angustifolia) or purple (Echinacea purpurea) echinacea, and optionally 0.1 to 1% of visnadine and/or esculoside. The composition is applied for treatment of ulcers caused by blood stasis in the lower limbs veins.EFFECT: composition has synergistic activity in the treatment of ulcers caused by blood stasis in the lower limbs veins.3 cl, 1 tbl, 3 ex
Composition for wounds treatment // 2619351
FIELD: pharmacy.SUBSTANCE: invention is represented by an anhydrous composition for wound treatment, comprising (a) a discontinuous hydrophilic phase containing thermolysin and PEG 400, and (b) a continuous hydrophobic phase containing a hydrophobic base. The discontinuous hydrophilic phase is dispersed in the continuous hydrophobic phase. Composition versions include trypsin, papain, or pepsin.EFFECT: enhanced enzymatic activity.8 cl, 9 ex, 13 tbl, 10 dwg
ethod for soft tissues defects treatment in patients with diabetic foot syndrome // 2619257
FIELD: medicine.SUBSTANCE: first, the wound defect surface in the defect bottom and walls area and in hyperkeratosis areas is cleansed. Then, "collost" biomaterial is implanted in the defect bottom and walls tissues to a depth of 0.3-0.5 cm in the form of a gel 15% with a syringe to form channels filled with gel. At that, the angle of needle insertion is set from 15° to 45° to the defect surface at the injection point. After implantation, the surface of the defect and the collagen canals are covered with a wound coating with G-Derm histoequivalent, followed by application of a dressing with an antiseptic solution which is moisturized twice a day.EFFECT: efficacy and reduction of duration of ulcerative soft tissue defects local treatment for patients with diabetic foot syndrome.2 cl, 9 dwg, 2 ex

ethod for prophylactic treatment in case ofneoplastic processes involving skin tissue, such as melanoma, basal cell and squamous cell carcinoma // 2619208
FIELD: medicine.SUBSTANCE: for prophylactic treatment in case of neoplastic processes involving skin tissue, such as melanoma, basal cell carcinoma, squamous cell carcinoma, a pharmaceutical preparation is used comprising a protein-polypeptide complex (BPC) in the form of cosmetic compositions, such as day or night creams, gels, alone or in liposomal form, and also as a photoactive or photoprotective compositions as the active substance, daily at a concentration of 0.001-0.05 mg/ml 1-2 times a day with a dose of 10-20 days course not less than 4 courses per year. The active substance is a protein-polypeptide complex produced of hoofed farm animal's nerve and skin embryonic tissue homogenate and containing negatively charged weak-acid and neutral proteins and polypeptides with molecular weight from 5 to 200 kDa and containing an average molecular weight fraction within 10 to 120 kDa of not less than 80%, with the total protein concentration of 0.2-4.2 mg/ml, the ultraviolet spectrum absorption peak of the solution at wave length± 2805 nm, the UV-visible spectrum peak at wave length 274-284 nm, the presence of specific bands in the range of pl from 4.2 to 8.4 in isoelectric focusing in 5% polyacrylamide gel.EFFECT: invention provides prevention of neoplastic skin diseases.2 dwg, 6 ex
ethod for skin hemangiomas treatment using silicone coating // 2618457
FIELD: medicine.SUBSTANCE: silicone coating is applied to the hemangioma area with a mandatory capture of at least 2.0 cm of healthy skin around the formation, then the applied coating is allowed to dry without covering it with clothing until an invisible "film" (for example, for 4-5 minutes) is formed, at that, the silicone coating is applied 2 times a day. The silicone coating is a mixture of polymeric organosilicon compounds - polysiloxanes, with addition of an inorganic silicon compound - silicon dioxide.EFFECT: method allows to improve the cosmetic result of treatment.3 cl, 3 ex
ethod of producing ointment for treatment of pyoinflammatory and necrotic processes in limb distal segment of cattle // 2618400
FIELD: veterinary medicine.SUBSTANCE: invention is intended for the production of an anti-inflammatory ointment for the treatment of pyoinflammatory and necrotic processes in the limb distal segment of cattle. The method consists in mixing molten wax, pinewood tar, pine resin, lithol and methyluracil in the following ratio, wt %: pinewood tar - 25.0; gum - 25.0; wax - 8.0; lithol - 40.0; methyluracil 2.0.EFFECT: use of the claimed invention makes it possible to produce a highly effective ointment for the treatment of pyoinflammatory and necrotic processes in the limb distal segment of cattle.2 ex
Anti-burn agent based on aspen leaves, flowers of calendula, wild camomile // 2618087
FIELD: pharmacology.SUBSTANCE: anti-burn agent containing an infusion of aspen leaves; infusion of chamomile flowers; infusion of flowers of calendula officinalis; essential oil of lavender medicinal; almond oil; gelatin crystal; furacilin; anesthesin; glycerin, taken in a certain ratio.EFFECT: drug has an increased anti-inflammatory, regenerating, antioxidant and antimicrobial action, characterized by the absence of allergic action.3 tbl, 5 dwg
Derivatives of 5-substituted quinazolinone, compositions containing them and methods of application thereof // 2617989
FIELD: pharmaceutics.SUBSTANCE: compounds of formula (I) R1 is halogen atom; (C1-C6) alkyl, optionally substituted with one or more halogen atoms; (C1-C6) alkoxy group, optionally substituted with one or more halogen atoms, or -(CH2)nNHRa, where Ra represents hydrogen atom; -C(O)-(CH2)n-phenyl or -C(O)-(CH2)n-pyridyl, where phenyl is optionally substituted with one or more substitutes of halogen atom; -SCF3; (C1-C6)alkyl, optionally substituted with one or more halogen atoms, or (C1-C6)alkoxy group, optionally substituted with one or more halogen atoms; -C(O)-(C1-C8)alkyl, where alkyl is optionally substituted with one or more halogen atoms; -C(O)-(CH2)n-(C3-C10-cycloalkyl); -C(O)-(CH2)n-NRbRc, where Rb and Rc are hydrogen atoms independently of each other; (C1-C6)alkyl; or phenyl, optionally substituted with one or more substitutes of halogen atom or (C1-C6)alkyl; -C(O)-(CH2)n-O-(C1-C6)alkyl; or -C(O)-(CH2)n-O-(CH2)n-phenyl; R2 is hydrogen atom; OH; phenyl or (C1-C6) alkyl, optionally substituted with one or more halogen atoms; R3 is hydrogen atom; or (C1-C6) alkyl; and n takes values 0, 1 or 2.EFFECT: method is disclosed of treating or controlling diseases or disorders, such as cancer involving administering 5-substituted quinazoline compound of formula (I) or its pharmaceutically acceptable salt, solvate or stereoisomer.32 cl, 59 ex
ethod of treatment of infantile hemangiomas // 2617516
FIELD: medicine.SUBSTANCE: for the treatment of infantile hemangiomas with atenolol in children aged 1 month to 3 years old with infantile hemangiomas any form, in the active growth phase, prescribed atenolol at a dose of 0.5 to 1.0 mg/kg body weight of the child per day in 2 receiving the daily dose is divided into equal parts and give every 12 hours. Atenolol administered in two stages, the starting dose of 0.5 mg/kg/day, therapeutic dosage - 1.0 mg/kg/day, treatment of 4 to 6 months. And children from 1 month to 3 months of life, the recommended maximum dose of 0.5 mg/kg body weight, use of the drug on the ECG monitor and holterovsokom monitoring, the drug is prescribed after a cardiac examination, removal of the drug takes place gradually over a period of two weeks, at first, in the first week, atenolol administered at the rate of 50% of the therapeutic dosage in the second week, the drug is prescribed for 25% of the therapeutic dosage. The effectiveness of treatment was assessed a month from the date of the appointment, then every 2 months from the date of initiation of therapy.EFFECT: blanching of the hemangioma and the reduction of its size.2 dwg, 2 ex
Bacteriorhodopsin application as cosmetic and/or therapeutic agent for complex treatment of dermatoses // 2617425
FIELD: medicine.SUBSTANCE: invention is the use of an aqueous solution of Halobacterium salinarum VKPM B-11850 halophilic bacteria strain bacteriorhodopsin comprising bacteriorhodopsin in a concentration of 0.24-0.75%, as a cosmetic agent for skin care, or as a therapeutic agent for the combined treatment of dermatoses.EFFECT: expansion of the arsenal of means for skin care and comprehensive treatment of dermatoses.2 cl, 4 ex
Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as inhibitors // 2617401
FIELD: chemistry.SUBSTANCE: invention relates to compounds of general formula (I) (I), where: R1 and R2, which can be identical or different, independently selected from a group consisting of: - (C1-C6)alkyl, optionally substituted (C3-C7)cycloalkyl; - (C1-C6)halogenalkyl; - (C3-C7)cycloalkyl and - (C3-C7)heterocycloalkyl, containing heteroatom O; R3 represents hydrogen, (C1-C6)alkyl or (C1-C3)alkylthio(C1-C6)alkyl; A is a partially unsaturated or unsaturated bicyclic ring system consisting of two condensed monocyclic ring systems B and C, presented in cl. 1 of formula, where ring C is a monocyclic aryl or monocyclic heteroaryl ring system, ring B is a 5- or 6-member heterocycloalkyl group, zero of Y groups is bonded to ring C, n of groups Y is bonded to ring B, and n is an integer from 1 to 3; and where ring B and C optionally contains additional heteroatoms in amount of 1 to 4, selected from N, O or S; p is an integer from 0 to 3; Y denotes oxo group; K is selected from a group consisting of: - (C1-C6)alkyl, optionally substituted with one (C3-C7)cycloalkyl group; - (C3-C6)heterocycloalkyl(C1-C4)alkyl containing 1 or 2 heteroatoms selected from N or O; - (C3-C6)heterocycloalkyl containing 1 or 2 heteroatoms selected from N or O, optionally substituted with one or more (C1-C6)alkyl group; - (C1-C4)halogenalkyl; - OR4, where R4 selected from a group consisting of: - H; - (C1-C6)alkyl, optionally substituted (C3-C7)cycloalkyl or heteroaryl; - halogen atoms; - CN; - NO2; - NR5R6, where R5 and R6, which can be identical or different, independently selected from a group consisting of: - H; - OH; - (C1-C4)alkyl-NR7R8, where R7 and R8, which can be identical or different, independently selected from a group consisting of: H; (C1-C6)alkyl, possibly substituted (C1-C6)alkoxyl; and (C1-C6)alkyl-NR9R10, where R9 and R10, which can be identical or different, represent H or (C1-C6)alkyl; or they form together with a nitrogen atom to which they are bonded, (C3-C6)heterocycloalkyl ring containing 1 or 2 heteroatoms, selected from N, O or S, optionally substituted (C1-C6)alkyl or (C1-C6)alkylcarbonyl group; -(C1-C6)alkyl, optionally substituted with (C1-C6)alkoxyl or heteroaryl, (C3-C6)heterocycloalkylcarbonyl containing 1 or 2 heteroatoms selected from N or O, heteroarylcarbonyl, wherein all of them may further be substituted with one or more (C1-C6)alkyl, (C1-C6)halogenalkyl or (C1-C6)alkoxyl groups, which are identical or different and are selected independently; - SO2R11, where R11 represents (C1-C6)alkyl; - C(O)R12, where R12 is (C1-C6)alkyl, optionally substituted with (C1-C6)alkoxyl; - (C1-C4)alkyl-NR13R14, where R13 and R14, which can be identical or different, are independently selected from a group consisting of groups: - SO2(C1-C6)alkyl, H, (C1-C6)alkyl and (C3-C7)heterocycloalkyl(C1-C4)alkyl containing 1 or 2 heteroatoms selected from N or O; and - SO2NR15R16, where R15 and R16, which can be identical or different, independently represent H or (C1-C6)alkyl; where groups with R4 at R16 have similar or different values in each case, if they are present in more than one group; and where heteroaryl is a mono- or bicyclic ring system with 5–10 ring atoms, containing 1 or 2 heteroatoms selected from N, O or S; or its pyridine-N-oxides, pharmaceutically acceptable salts or solvates. As well as to methods of producing such compounds, compositions containing them and their therapeutic application as inhibitors of phosphodiesterase 4 (PDE4) enzyme.EFFECT: disclosed are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as inhibitors.16 cl, 16 tbl, 52 ex

Antiinflammatory pharmaceutical composition for topical use in form of cream with cylaytonum // 2616254
FIELD: pharmacology.SUBSTANCE: invention is an antiinflammatory pharmaceutical composition for topical use in the form of a cream comprising 0.05-2 wt % of cylaytonum as an active component, 30-34 wt % of water, 36-40 wt % of white petrolatum, 4-8 wt % of white beeswax, 16-22 wt % of propylene glycol, 2-6 wt % of phospholipin 90H and 0.005-0.04 wt % of preservative agent.EFFECT: stability at ambient temperature and toxicity reduction.11 cl, 14 tbl, 4 dwg
ethod for preparation of bioactive sorption-helium composition // 2616250
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to the pharmaceutical industry, namely to a method for preparation of bioactive sorption-helium composition based on modified montmorillonite-containing clay. The method for preparation of bioactive sorption-helium composition based on modified montmorillonite-containing clay for treatment of pyoinflammatory wounds, including modification of the enriched montmorillonite-containing clay with alcoholic extracts of medicinal plants, with an antiseptic effect, drying of the finished phytomineralsorbent, grinding to powder and dispersing in water together with hydroxyethyl cellulose (HEC), then, if necessary, polyvinylpyrrolidone (PVP) is added to the resulting dispersion and is further dispersed under certain conditions, at that, the components for the method are taken with a certain ratio.EFFECT: invention provides bioactive sorption-helium composition based on montmorillonite-containing clay, which allows creation of a vapor permeable coating on the wound and does not interfere with the process of epithelialization.2 dwg, 2 ex
ethod for erosive and ulcerative skin lesions treatment // 2616239
FIELD: pharmacy.SUBSTANCE: method for autologous platelet-rich plasma manufacture includes blood withdrawal from patient's peripheral vein into vacuum tubes, blood mixing with sodium citrate by tubes revolution, centrifugation, platelet-rich autologous plasma upper layer exctration into a separate tube, platelet-rich autologous plasma exctracted upper layer activation by calcium ions by calcium gluconate addition into the tube, the obtained liquid is stirred by tube revolution under certain conditions. The method for erosive and ulcerative skin lesions treatment by means of autologous platelet-rich plasma.EFFECT: method allows to obtain autologous platelet-rich plasma, with intense reparative having activity against erosive and ulcerative skin lesions, the resulting effect is persistent and characterized by absence of recurrence.9 cl, 1 ex
Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethylindol-1-yl)-acetic acid // 2616000
FIELD: chemistry.SUBSTANCE: invention relates to organic chemistry, specifically to a stable solid dispersion (5-fluoro-2-methyl-3-quinolin-2-ylmethylindol-1-yl)-acetic acid (Compounds 1), containing amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethylindol-1-yl)-acetic acid (Compound 1) or its pharmaceutically or veterinarily acceptable salt and polymer, selected from polyvinylpyrrolidone (PVP), polyvinylpyrrolidone-vinyl acetate copolymer (PVP-VA), hydroxypropyl methylcellulose (HPMC) and hypromellose acetate succinate (HPMC AS) and their mixtures. Invention also relates to a method of producing said stable solid dispersion, its application, method of treating said diseases and pharmaceutical composition based on stable solid dispersion.EFFECT: obtaining a stable solid dispersion based on amorphous compound 1 and polymer, useful for treating or preventing diseases mediated by prostaglandin D2 (PGD2) or other agonists, acting on CRTH2 receptor.22 cl, 17 dwg, 15 tbl, 13 ex

ethod, test tube and device for making of compositions for wound healing // 2614722
FIELD: medicine; pharmaceuticals.SUBSTANCE: group of inventions relates to pharmaceutics and medicine and concerns method of making composition for healing of wounds and tissues including sampling of whole blood in test tube containing hyaluronic acid without mixing of whole blood and hyaluronic acid, centrifugation of said test tube and collection of supernatant containing said hyaluronic acid and platelet rich plasma. Composition obtained using said methods is used as matrix, cell nutrient medium or medium for implantation of cells and can be used in surgery, dentistry, orthopedics, mesotherapy, as well as in cosmetics and/or esthetics.EFFECT: group of inventions provides immediate use of obtained autologous blood cells with simultaneous preservation of their integrity for wound healing.25 cl, 14 ex, 16 dwg
ulticomponent therapy method for lower limb trophic ulcers of venous etiology // 2614666
FIELD: medicine.SUBSTANCE: multicomponent therapy is applied including infusion and topical treatment. For I degree ulcers, trental 2% 1.3 mg/kg and 0.9% NaCl - 200 ml is introduced, Detralex is prescribed as 1 capsule 2 times a day, and 10 procedures of wound treatment with nitric oxide (NO) using the "PLASON" device at a distance of 15-20 cm from the wound surface are performed within 10 seconds per 1 cm2 of area at NO temperature of 40°C, and NO concentration of 750 ppm with subsequent superimposition of a dressings with Kvotlan gel onto the trophic ulcer for a day. For II degree ulcers, Actovegin soultion is added to the complex for infusion at a dose of 4 mg/ml 0.9% NaCl - 250 ml and the time of ulcer treatment with nitric oxide is increased to 30 sec per 1 cm2 of area. For III degree ulcers, Activegin solution dosage in the treatment complex for infusion is increased to 8 mg/ml, and the time of ulcer treatment with nitric oxide is increased to 60 sec per 1 cm2 of area.EFFECT: increased efficiency and reduced terms of treatment due to complex antioxidant, regenerative and vasoprotective action of the claimed therapeutic complex.1 ex